Peptide legality lookup.
For each of 44 research peptides, this tool surfaces the FDA approval status, DEA schedule, 503A compounding posture, recent FDA Warning Letters, WADA/USADA/NCAA sport-body status, and any material state-level divergence — drawn from primary sources only, with verification dates on every citation.
Look up a compound × state
FREE · NO ACCOUNTHow it works
3 LEGAL LAYERSWhat we cover
Each compound × state page surfaces three legal layers: (1) the federal posture — FDA approval / investigational / unapproved status, DEA scheduling, §503A compounding bulks-list status, PCAC review history, recent FDA Warning Letters, and the “research-use-only” sale-framing enforcement posture; (2) the state-specific layer — currently the ~12 states with material divergence from federal (controlled-substance scheduling, AG consumer-protection actions, telehealth restrictions, pharmacy-board enforcement); and (3) the sport-body layer — WADA 2026, USADA, NCAA banned-substance status with class codes.
Methodology
Every status field is sourced to a primary document — FDA Warning Letter, DEA orange book, WADA prohibited list PDF, state AG press release, or pharmacy-board order — with the verification date recorded inline. We do not cite secondary reporting except as background. When we couldn’t verify a specific claim against a primary source, the page lists it explicitly rather than asserting it. Every record has a lastVerified date.
Disclaimer
This is a research reference. It is not legal advice, not medical guidance, and not a substitute for either. Statuses change — FDA, DEA, WADA, and state AGs update their positions independently and frequently. The verified-date stamps are the floor on how current the entry is. Before making any decision that depends on this data, consult a licensed pharmacist or a licensed attorney in your jurisdiction.
What we couldn't verify
10 OPEN QUESTIONS- OEHHA Prop 65 status not directly verified against the master list for every compound.
- Personal-possession enforcement posture is FDA-statement-based, not a positive legal exemption.
- WADA capture under S0 (non-approved substances) and S2 (peptide hormones) is class-effect based, not always explicitly named.
- State pharmacy-board enforcement actions are surfaced where AG press releases exist; private board orders may not be public.
- Telehealth-specific peptide restrictions are an emerging area — state medical-board guidance often lags statutes.
- Athletic-commission bans below the national-league level (state boxing/MMA commissions) are not exhaustively crawled.
- Import status via personal-import-package guidance is FDA-discretionary and changes without rulemaking.
- Compounding pharmacy 503A vs 503B distinctions are not surfaced per-state; only federal bulks-list status is tracked.
- Veterinary-channel diversion (compounds also marketed for animal research) is not separately scoped.
- Recent Warning Letter cadence is captured to the verifiedDate; new enforcement actions may have landed since.